GRTS

Gritstone bio, Inc.

2.03 USD
+0.01 (+0.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Gritstone bio, Inc. stock is down -11.74% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 1 CALL, 9 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Jan 16:34 16 Feb, 2024 2.50 CALL 456 5441
29 Jan 16:08 17 May, 2024 7.50 PUT 78 78
12 Feb 19:23 19 Apr, 2024 2.50 PUT 1985 99
20 Feb 20:07 19 Apr, 2024 2.50 PUT 500 2288
23 Feb 15:29 19 Apr, 2024 2.50 PUT 500 3000
23 Feb 19:27 19 Apr, 2024 2.50 PUT 394 3000
27 Feb 15:43 19 Apr, 2024 2.50 PUT 309 4051
27 Feb 15:48 17 May, 2024 2.50 PUT 219 512
01 Mar 16:11 19 Apr, 2024 2.50 PUT 224 6620
01 Mar 17:08 19 Apr, 2024 2.50 PUT 495 6620

About Gritstone bio, Inc.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for common solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine